ABSTRACT
Hodgkin lymphoma (HL) is a highly curable disease, and even in advanced-stage patients, more than 90% of them can achieve long-term survival. Due to its few adverse reactions and good curative effect, the ABVD regimen is currently used as the standard first-line chemotherapy for HL. In order to further improve the efficacy, the new first-line combination therapies and salvage therapeutic regimens for relapsed/refractory HL are continuously updated, such as anti-CD30 monoclonal antibody brentuximab vedotin combined with immune checkpoint inhibitors or chemotherapy, programmed death receptor 1 with chemotherapy or chimeric antigen receptor T-cells are gradually showing their advantages. This article summarizes the treatment progress of HL at the 61st American Society of Hematology Annual Meeting 2019.
ABSTRACT
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy and who are not candidates for stem cell transplantation have limited effective treatment options, resulting in a poor prognosis, thus, treatments with novel mechanisms of action are urgently needed. In the 60th American Society of Hematology (ASH) Annual Meeting, detailed reports focused on the research progresses of single agent, drug combination and chimeric antigen receptor T cell (CAR-T) therapy, providing more treatment options for R/R DLBCL patients.